Evaluation of the Impact of Vitrification on Oocytes
Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes
Studie Overzicht
Gedetailleerde beschrijving
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Cryopreservation of human oocytes has a great potential to preserve or extend fertility in the face of disease whose treatment would result in a loss of ovarian function. (malignancy, severe autoimmune disease, etc.). It would also provide a means of quarantining oocytes to be used in oocyte donation to provide the lowest possible risk of infection.
There are two methods for storage of oocytes: slow freezing or vitrification. Slow freezing is the conventional method and has been successfully used for embryos since 1983 and more recently for oocytes. Recent reports indicate that vitrification may be more successful than slow freezing. However, the technique has not been rigorously validated to date. The aim of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.
Patients will undergo ovarian stimulation for in vitro fertilization (IVF) according to the protocol recommended by their primary doctor. After retrieval, mature oocytes will be divided in half. One half will undergo vitrification, immediate thaw and intracytoplasmic sperm injection (ICSI). The other half will undergo just ICSI. All embryos will then develop on identical culture until day 3 or day 5. Prior to transfer, the best embryo from each group will undergo biopsy for genetic fingerprinting. The patient will have a 2 embryo transfer (one from each group). All extra embryos will be biopsied for pre-implantation genetic diagnosis (PGD) prior to being cryopreserved. If the patient becomes pregnant, we will follow up with an additional blood draw at approximately 9 weeks gestation and buccal swabs after the delivery of the infant(s).
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Reproductive Medicine Associates of new Jersey
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18104
- Reproductive Medicine Assoicates of PA at Lehigh Valley
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Inclusion Criteria:
- No prior failed IVF treatment cycle
- Female partner less than 35 years of age at time of onset of the IVF cycle
- Normal maximum prior day 3 follicle stimulating hormone (FSH) level (< or = 10 IU/L)
- Total basal antral follicle count greater than or equal to 12
- Male partner with greater than 100,000 total motile spermatozoa Donor sperm is acceptable but the couples will be required to provide one additional vial for DNA analysis
- Body Mass Index (BMI) ≤ 32 kg/m2
Exclusion Criteria:
- Diagnosis of chronic oligoovulation or anovulation (cycle typically occurring less often than every 38 days)
- Diagnosis of endometrial insufficiency
- Clinical indication for PGD (undergoing IVF with PGD to rule out a known genetic defect)
- Use of testicular aspiration or biopsy procedures to obtain sperm
- Unevaluated ovarian mass
- Presence of hydrosalpinges which communicate with the endometrial cavity
- Any contraindication to undergoing in vitro fertilization or gonadotropin stimulation
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Oocyte Vitrification
Each patient will have oocytes randomized into two groups immediately after retrieval.
Half of oocytes will be vitrified, thawed and inseminated.
The other half will be inseminated only.
All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups).
Following delivery, buccal swabs will be collected on all infants.
|
Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination.
All embryos will undergo biopsy for PGD prior to transfer.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Aneuploidy Rate (evaluation of whether embryo is chromosomally normal)
Tijdsspanne: 1 year
|
Compare the rate of chromosomally-abnormal embryos among embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
|
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Delivery rates
Tijdsspanne: 1 year
|
All embryos will be biopsied prior to transfer and DNA samples will be collected from all infants.
Compare embryonic and infant DNA to evaluate whether the live birth resulted from a vitrified or a fresh/control oocyte.
|
1 year
|
|
Paired Sustained Implantation Rate (number of viable fetuses beyond the first trimester per embryo transferred)
Tijdsspanne: 1 year
|
Among patients with a paired two blastocyst transfer, compare the implantation rate of embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
|
1 year
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Richard T Scott, MD, Reproductive Medicine Associates of new Jersey
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- RMA-2010-02
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .